Observational studySupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Risk factors for chemotherapy-induced dysgeusia in patients receiving dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy: a retrospective observational study.
Observational study in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChemotherapy-induced (CI) dysgeusia is a common adverse event that impairs nutritional status and quality of life; however, its risk factors remain poorly understood. This study aimed to identify risk factors for CI dysgeusia in patients receiving dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) therapy.
methodsWe conducted a single-center retrospective observational study including patients with urothelial carcinoma who received dd-MVAC therapy between August 2018 and March 2023. CI dysgeusia was defined as grade ≥ 2 dysgeusia according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Univariable logistic regression was performed to screen candidate predictors (p < 0.20), followed by multivariable logistic regression with backward stepwise selection. Cutoff values were determined using receiver operating characteristic (ROC) analysis. Predictive performance was evaluated using positive predictive value (PPV) and negative predictive value (NPV).
resultsAmong 103 patients, 32 (31.1%) developed CI dysgeusia. Multivariable analysis identified depression (adjusted odds ratio [aOR] 23.3, 95% CI 3.01-529; p = 0.010) and HbA1c ≤ 5.8% (aOR 2.86, 95% CI 1.16-7.30; p = 0.024) as independent risk factors. Depression alone showed good predictive performance (PPV 83.3%; NPV 72.2%) and combining it with HbA1c ≤ 5.8% increased PPV to 100%.
conclusionsDepression and HbA1c ≤ 5.8% were independent risk factors for CI dysgeusia in patients undergoing dd-MVAC therapy. These findings suggest that readily available clinical information may enable early identification of high-risk patients and support individualized supportive care strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.